Directorate of Research and Civil Affairs

Advancements in reproductive medicine available at Shady Grove Fertility (SGF) can reduce the inheritance of genetic diseases like breast cancer

Thursday, October 14, 2021 - 1:45pm

Individuals and couples with known genetic diseases can turn to Shady Grove Fertility (SGF) to undergo in vitro fertilization (IVF) with preimplantation genetic testing for monogenic/single gene defects(PGT-M) to reduce the risk of passing genetic mutations to future offspring.

Key Points: 
  • Individuals and couples with known genetic diseases can turn to Shady Grove Fertility (SGF) to undergo in vitro fertilization (IVF) with preimplantation genetic testing for monogenic/single gene defects(PGT-M) to reduce the risk of passing genetic mutations to future offspring.
  • Additionally, patients at risk for dominant gene mutations, such as breast cancer or inherited forms of colon cancer, can have individualized testing for these diseases.
  • While Rose is not a carrier for the breast cancer gene, she is a carrier of a rare X-linked genetic mutation called Wiskott-Aldrich syndrome.
  • We are so fortunate to live in a world where we can now reduce the inheritance of deadly genetic diseases via IVF.

Limbix Expands Leadership Team to Support Development of SparkRx Digital Therapeutic for Depression in Adolescents

Wednesday, September 22, 2021 - 1:00pm

We trust that they will continue to hold our digital therapeutics to the highest scientific and clinical standards.

Key Points: 
  • We trust that they will continue to hold our digital therapeutics to the highest scientific and clinical standards.
  • As Chief Research Officer, Dr. Padmanabhan will be responsible for the research efforts that support the development and clinical validation of Limbixs prescription digital therapeutics.
  • Limbix is a prescription digital therapeutic company passionate about creating mental health treatments for adolescents.
  • Their first digital therapeutic, Limbix SparkRx, will be available this fall for licensed healthcare professionals to offer to patients nationwide.

PsiloThera, Inc. a Leader in Psychedelic Healthcare Innovation Announces the Filing of U. S. Patents Protecting Its Proprietary Psychedelic Therapeutic Process, Tele-Mental Healthcare & Microdosing Online Platform

Thursday, September 9, 2021 - 1:08pm

PsiloThers's Tele-MentalHealthcare & Microdosing Platform will provide specialized programs which significantly increase the access to focused-evaluation and life-changing therapy for Veterans, 1st Responders and Patients with treatment resistant mental illnesses.

Key Points: 
  • PsiloThers's Tele-MentalHealthcare & Microdosing Platform will provide specialized programs which significantly increase the access to focused-evaluation and life-changing therapy for Veterans, 1st Responders and Patients with treatment resistant mental illnesses.
  • PsiloThera CEO, John Atanasio states, "PsiloThera's first U.S. Patent filing is just the beginning of our intellectual property portfolio strategy to protect PsiloThera's scientific and medical discoveries, technology breakthroughs & proprietary therapeutic processes."
  • "Also, Mental Health Professionals will greatly benefit by using PsiloThera's Tele-Mental Healthcare & Microdosing Platform to easily refer Patients for psilocybin therapies.
  • "I am absolutely passionate about helping our Vets and 1st Responders as well as partnering with the Mental Health Community."